Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Accuracy of Detecting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: the preSINO Trial (Pre-Surgery If Needed for Oesophageal Cancer)

NCT03937362 is registered in ClinicalTrials.gov with Shanghai Chest Hospital as lead sponsor.

NCT NCT03937362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03937362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Accuracy of Detecting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: the preSINO Trial (Pre-Surgery If Needed for Oesophageal Cancer)
Lead sponsor
Shanghai Chest Hospital
Phase
Observational
Overall status
Completed
Start date
August 8, 2019
Completion date
May 31, 2024
Enrollment
200 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer